Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

Publisher： Karger

E-ISSN： 1421-9794|61|3|122-126

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.3, 2016-01, pp. : 122-126

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients

By  

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 127-133

Karger

Access to resources Recommend Favorite

Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity

By  

Chemotherapy, Vol. 55, Iss. 6, 2009-11 ,pp. : 391-398

Karger

Access to resources Recommend Favorite

Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-07 ,pp. : 225-232

Karger

Access to resources Recommend Favorite

Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients

By  

Chemotherapy, Vol. 48, Iss. 5, 2002-12 ,pp. : 252-258

Karger

Access to resources Recommend Favorite

A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors

By  

Chemotherapy, Vol. 55, Iss. 6, 2009-12 ,pp. : 441-445

Karger

Access to resources Recommend Favorite